Compare FNWD & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | CGEN |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.0M | 148.7M |
| IPO Year | 1996 | 2001 |
| Metric | FNWD | CGEN |
|---|---|---|
| Price | $36.41 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $34.00 | $4.00 |
| AVG Volume (30 Days) | 4.2K | ★ 308.3K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 44.90 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | $58.57 |
| P/E Ratio | $25.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $1.13 |
| 52 Week High | $39.99 | $2.38 |
| Indicator | FNWD | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 59.74 |
| Support Level | $36.37 | $1.45 |
| Resistance Level | $38.75 | $2.38 |
| Average True Range (ATR) | 1.02 | 0.15 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 64.55 | 67.56 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.